Serum Bile Acid Levels in Children with Nonalcoholic Fatty Liver Disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 61, Issue 1, 2015, Pages 85-90

  Jahnel, Jörg ^a   Zöhrer, Evelyn ^a   Alisi, Anna ^b   Ferrari, Federica ^b   Ceccarelli, Sara ^b   De Vito, Rita ^b   Scharnagl, Hubert ^a   Stojakovic, Tatjana ^a   Fauler, Günter ^a   Trauner, Michael ^c   Nobili, Valerio ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

bile acids; children; fibroblast growth factor 19; hyperinsulinemia; liver fibrosis; nonalcoholic fatty liver disease; steatosis; TGR5

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILE ACID; BIOLOGICAL MARKER; CHENODEOXYCHOLIC ACID; CHOLIC ACID; DEOXYCHOLIC ACID; FIBROBLAST GROWTH FACTOR 19; GLUCOSE; GLYCINE; INSULIN; LITHOCHOLIC ACID; TAURINE; URSODEOXYCHOLIC ACID;

ADOLESCENT; ADULT; ARTICLE; BILE ACID BLOOD LEVEL; BLOOD; CHILD; CHOLESTASIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; CASE CONTROL STUDY; COMPLICATION; DISEASE COURSE; LIVER; LIVER CIRRHOSIS; PATHOLOGY; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; BILE ACIDS AND SALTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; YOUNG ADULT;

EID: 84937720295     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000774     Document Type: Article

References (37)

1. Nobili V, Svegliati-Baroni G, Alisi A, et al. A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol 2013;58:1218-29.
2. Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics 2006;118:1388-93.
3. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010;103:71-83.
4. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128: 1898-906.
5. Nobili V, Alisi A, Torre G, et al. Hyaluronic acid predicts hepatic fibrosis in children with nonalcoholic fatty liver disease. Transl Res 2010;156:229-34.
6. Pearce SG, Thosani NC, Pan JJ. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res 2013;1:7.
7. Mannes GA, Stellaard F, Paumgartner G. Increased serum bile acids in cirrhosis with normal transaminases. Digestion 1982;25:217-21.
8. Fuchs C, Claudel T, Trauner M. Bile acid-mediated control of liver triglycerides. Semin Liver Dis 2013;33:330-42.
9. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009;10:167-77.
10. Trauner M, Claudel T, Fickert P, et al. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis 2010;28:220-4.
11. Park WH, Pak YK. Insulin-dependent suppression of cholesterol 7alpha-hydroxylase is a possible link between glucose and cholesterol metabolisms. Exp Mol Med 2011;43:571-9.
12. Prawitt J, Caron S, Staels B. Glucose-lowering effects of intestinal bile acid sequestration through enhancement of splanchnic glucose utilization. Trends Endocrinol Metab 2014;25:235-44.
13. Holt JA, Luo G, Billin AN, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003;17:1581-91.
14. Yu C, Wang F, Kan M, et al. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem 2000;275:15482-9.
15. Yu C, Wang F, Jin C, et al. Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids. J Biol Chem 2005;280:17707-14.
16. Cacciari E, Milani S, Balsamo A, et al. Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J Endocrinol Invest 2006;29:581-93.
17. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepa-tology 2005;41:1313-21.
18. Alisi A, Ceccarelli S, Panera N, et al. Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease. PLoS One 2013;8:e67160.
19. Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004;145:2594-603.
20. Andersen E, Karlaganis G, Sjovall J. Altered bile acid profiles in duodenal bile and urine in diabetic subjects. Eur J Clin Invest 1988;18:166-72.
21. Knop FK. Bile-induced secretion of glucagon-like peptide-1: patho-physiological implications in type 2 diabetes? Am J Physiol Endocrinol Metab 2010;299:E10-3.
22. Kir S, Kliewer SA, Mangelsdorf DJ. Roles of FGF19 in liver metabolism. Cold Spring Harb Symp Quant Biol 2011;76:139-44.
23. Mraz M, Lacinova Z, Kavalkova P, et al. Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-alpha agonist treatment. Physiol Res 2011;60:627-36.
24. Hofmann AF, Hagey LR. Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades. J Lipid Res 2014;55:1553-95.
25. Skoien R, Richardson MM, Jonsson JR, et al. Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. Liver Int 2013;33:624-32.
26. Chiba M, Sasaki M, Kitamura S, et al. Participation of bile ductular cells in the pathological progression of non-alcoholic fatty liver disease. J Clin Pathol 2011;64:564-70.
27. Jahnel J, Fickert P, Hauer AC, et al. Inflammatory bowel disease alters intestinal bile acid transporter expression. Drug Metab Dispos 2014;42:1423-31.
28. Ridlon JM, Kang DJ, Hylemon PB, et al. Bile acids and the gut microbiome. Curr Opin Gastroenterol 2014;30:332-8.
29. Perez MJ, Briz O. Bile-acid-induced cell injury and protection. World J Gastroenterol 2009;15:1677-89.
30. Song P, Zhang Y, Klaassen CD. Dose-response of five bile acids on serum and liver bile acid concentrations and hepatotoxicty in mice. Toxicol Sci 2011;123:359-67.
31. Maillette de Buy Wenniger L, Beuers U. Bile salts and cholestasis. Dig Liver Dis 2010;42:409-18.
32. Mitsuyoshi H, Nakashima T, Sumida Y, et al. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antiox-idants. Biochem Biophys Res Commun 1999;263:537-42.
33. Meinders AE, Van Berge Henegouwen GP, Willekens FL, et al. Biliary lipid and bile acid composition in insulin-dependent diabetes mellitus. Arguments for increased intestinal bacterial bile acid degradation. Dig Dis Sci 1981;26:402-8.
34. Wisse E, De Zanger RB, Charels K, et al. The liver sieve: considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of disse. Hepatology 1985;5:683-92.
35. Babbs C, Haboubi NY, Mellor JM, et al. Endothelial cell transformation in primary biliary cirrhosis: a morphological and biochemical study. Hepatology 1990;11:723-9.
36. Xu B, Broome U, Uzunel M, et al. Capillarization of hepatic sinusoid by liver endothelial cell-reactive autoantibodies in patients with cirrhosis and chronic hepatitis. Am J Pathol 2003;163:1275-89.
37. Fiorucci S, Rizzo G, Donini A, et al. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol Med 2007;13: 298-309.